Cargando…
A Novel Method for Studying the Pharmacokinetics of [(14)C]Umeclidinium After Application to the Axilla or Palm of Healthy Male Subjects
Umeclidinium (UMEC), a long‐acting muscarinic antagonist approved for chronic obstructive pulmonary disease (COPD), was investigated for primary hyperhidrosis as topical therapy. This study evaluated the pharmacokinetics, safety, and tolerability of a single dose of [(14)C]UMEC applied to either uno...
Autores principales: | Pene Dumitrescu, T, Santos, LL, Hughes, SC, Pereira, AI, Young, GC, Hussey, E, Charlton, P, Baptiste‐Brown, S, Stuart, JS, Vincent, V, van Marle, SP, Schmith, VD |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351336/ https://www.ncbi.nlm.nih.gov/pubmed/27304394 http://dx.doi.org/10.1111/cts.12406 |
Ejemplares similares
-
Pharmacometrics: Focus on the Patient
por: Dumitrescu, T Pene, et al.
Publicado: (2015) -
Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study
por: Mehta, Rashmi, et al.
Publicado: (2014) -
Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
por: Brealey, Noushin, et al.
Publicado: (2015) -
Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
Publicado: (2016) -
The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study
por: Requena, Gema, et al.
Publicado: (2021)